Published: January 2013
|Formats||Member Price||Nonmember Price|
|Individual Download||$99 / €80||$405 / €330|
|Which format is right for me?|
Recent survey results show that the pharmaceutical companies often take an overly conservative approach to NIMPs (or Non-IMPs) due to regulatory and operational ambiguity. This can lead to unnecessary expenses and process steps, which can needlessly complicate clinical trials.
The ISPE Good Practice Guide: Harmonizing the Definition and Use of Non-Investigational Medicinal Products (NIMPs) aims to provide practical operational guidance and drive a consistent industry approach to the use of NIMPs. The Guide contains criteria for classifying NIMPs and an overview of current NIMP regulatory requirements.
This in-depth Guide will help you properly manage NIMPs by providing guidance on:
Quality Risk Management for Legacy Products in CMOs
Thursday, 08 Dec 2016 14.12
Cleaning Buffer Preparation Tank Air–Liquid Interface Rings
Wednesday, 07 Dec 2016 13.12
Inaugural ISPE Biopharmaceutical Conference Opens in San Francisco
Tuesday, 06 Dec 2016 20.12